一项真实世界多中心研究，旨在评估奈妥匹坦联合帕洛诺司琼固定剂量复方制剂预防马来西亚接受中度或高度致吐化疗患者化疗引起的恶心和呕吐的安全性和有效性。

23 November 2021


Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng, John Seng Hooi Low, Kai Seng Lam, Radzi Bin Ahmad Ahmad Badruddin, Christina Nye Bing Lai, Kah Liew Lau, Kwang Jeat Chong, Joel Gabriel Nonis, Muhammad Azrif Ahmad Annuar, Mohd Haris Fadzillah Bin Abdul Rahman

在此查看研究
复制引用
已复制！

摘要

Aim

A large proportion of cancer patients are at high risk for chemotherapy-induced nausea and vomiting (CINV), but the choice of anti-emetics for CINV in Malaysia is limited.

Methods

This was a real-world study of a fixed-dose combination of netupitant and palonosetron (NEPA) to inhibit CINV in adult patients receiving moderately (MEC) or highly emetogenic chemotherapy (HEC) for solid/hematological malignancies at eight Malaysian centers. Each HEC/MEC cycle received one dose of NEPA + dexamethasone for CINV prevention. Complete response (no emesis, no rescue medication) (CR), no more than mild nausea (severity score ≤ 2.5), and complete control (CR) (no more than mild nausea) during the acute (0–24 h), delayed (25–120 h), and overall (0–120 h) phases post-chemotherapy were measured. Treatment-related adverse events (AEs) were recorded.

Results

During March 2016–April 2018 (NMRR-17-3286-38282), NEPA + dexamethasone was administered to 54 patients (77.8% solid, 22.2% hematological malignancies). Note that 59.3% received HEC, while 40.7% received MEC regimen. During the overall phase of the first cycle, the majority had CR (77.8%), no more than mild nausea (74.1%), and complete control (61.1%). Seventeen patients received two consecutive cycles at any point of chemotherapy cycles. During the overall phases across two consecutive cycles, all patients achieved CR, and the majority reported no more than mild nausea and complete control. No grades 3–4 AEs were reported.

Conclusions

NEPA had sustained efficacy and tolerability at first administration and across two cycles of MEC/HEC for CINV prevention.

参考资料

  1. Morrow, G. R., Navari, R. M., & Rugo, H. S. (2014). Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clinical Advances in Hematology & Oncology, 12(3, Suppl. 9), 1–14.
  2. Van den Brande, J., Brouwer, A., & Peeters, M. (2014). Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: Review and focus on the Belgian situation. Acta Gastro-Enterologica Belgica, 77(2), 240–248.
  3. Palli, S. R., Grabner, M., Quimbo, R. A., & Rugo, H. S. (2015). The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Management and Research, 7, 175–188. https://doi.org/10.2147/CMAR.S83116
  4. Chan, H. K., & Ismail, S. (2014). Side effects of chemotherapy among cancer patients in a Malaysian General Hospital: Experiences, perceptions and informational needs from clinical pharmacists. Asian Pacific Journal of Cancer Prevention, 15(13), 5305–5309. https://doi.org/10.7314/apjcp.2014.15.13.5305
  5. Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Maranzano, E., Guidani, F., Feyer, P., & MASCC and ESMO Guidelines Committee. (2016). MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology, 27(Suppl. 5), v119–v133. https://doi.org/10.1093/annonc/mdw270
  6. Berger, M. J., Ettinger, D. S., Aston, J., Barbour, S., Bergsbaken, J., Bierman, P. J., Brandstetter, C., Cobaugh, D. J., DeBaun, B., Einhorn, L. H., Kim, E. Y., Lilly, E. S., Martinez, E. M., Nabell, L. M., National Comprehensive Cancer Network, Noonan, K., Powers, J. G., Scullion, B., Starnes, L., ... Gursalu, S. (2017). Antiemesis, Version 2.2017: Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 15(7), 883–893. https://doi.org/10.6004/jnccn.2017.0117
  7. European Medicines Agency. (2018). Summary of product characteristics (Akynzeo). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003728/WC500188432.pdf
  8. Rizzi, A., Campi, B., Camarda, V., Cazzola, M., Gavioli, R., Spagnolo, B., Marzola, E., Civelli, O., Regoli, D., Pietra, C., & Guerrini, R. (2012). In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist netupitant. Peptides, 37(1), 86–97. https://doi.org/10.1016/j.peptides.2012.06.012
  9. Rossi, G., Tilola, S. O., & Rudengren, C. (2012). A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [Abstract]. Journal of Clinical Oncology, 30(15_suppl), Article 9054. https://doi.org/10.1200/jco.2012.30.15_suppl.9054
  10. Rojas, C., & Slusher, B. S. (2012). Pharmacological mechanism of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. European Journal of Pharmacology, 684(1–3), 1–7. https://doi.org/10.1016/j.ejphar.2012.03.033
  11. Lorusso, V., Karthaus, M., & Aapro, M. (2015). Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting. Future Oncology, 11(4), 565–577. https://doi.org/10.2217/fon.14.269
  12. Cawston, H., Bourhis, F., Eriksson, J., Sassi, F., & Aapro, M. (2017). NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs in Context, 6, Article 212298. https://doi.org/10.7573/dic.212298
  13. Restelli, U., Saibene, G., Nardulli, P., Lorusso, V., & Croce, D. (2017). Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open, 7(7), Article e015645. https://doi.org/10.1136/bmjopen-2016-015645
  14. Kottschade, L., Novotny, P., Lyss, A., Mazurczak, M., Loprinzi, C., & Barton, D. (2016). Chemotherapy-induced nausea and vomiting: Incidence and characteristics of persistent symptoms and future directions NCCTG N08C3. Supportive Care in Cancer, 24(6), 2661–2667. https://doi.org/10.1007/s00520-015-3075-y
  15. Barton, D. L., Thanarajasingam, G., Sloan, J. A., Kottschade, L. A., Shaitelman, S. F., de Moraes, A. A. S., Satele, D. V., Mazurczak, M. A., & Loprinzi, C. L. (2014). Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer, 120(22), 3575–3583. https://doi.org/10.1002/cncr.28876
  16. Zhang, L., Lu, S., Feng, J., Dechaphunkul, A., Chang, J., Wang, D., Wu, L., Hu, X., Cheng, Y., Thongprasert, S., Chiu, J., Choi, I. S., Taylor, A., Rizzi, G., & Rossi, G. (2018). A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Annals of Oncology, 29(2), 452–458. https://doi.org/10.1093/annonc/mdx749
  17. Aapro, M., Karthaus, M., Schwartzberg, L., Borroni, B., Rizzi, G., & Rossi, G. (2017). NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: Results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer, 25(4), 1127–1135. https://doi.org/10.1007/s00520-016-3502-x
  18. Dranitsaris, G., Molassiotis, A., Clemons, M., Boodhan, S., Al-Hattab, R., Caley, K., & Navari, R. (2017). The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Annals of Oncology, 28(6), 1260–1267. https://doi.org/10.1093/annonc/mdx100
  19. Lorusso, V. (2016). Management of chemotherapy-induced nausea and vomiting by risk profile: Role of netupitant/palonosetron. Therapeutics and Clinical Risk Management, 12, 917–925. https://doi.org/10.2147/TCRM.S90558
  20. Rugo, H. S., Rossi, G., Rizzi, G., & Aapro, M. (2017). Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. The Breast, 33, 76–82. https://doi.org/10.1016/j.breast.2017.03.001
  21. Zhou, M., Popovic, M., Pasetka, M., Zhang, L., & DeAngelis, C. (2015). Update on the management of chemotherapy-induced nausea and vomiting – Focus on palonosetron. Therapeutics and Clinical Risk Management, 11, 713–729. https://doi.org/10.2147/TCRM.S44093
  22. Liau, C. T., Chu, N. M., Liu, H. E., Deuson, R., Lien, J., & Chen, J. S. (2005). Incidence of chemotherapy-induced nausea and vomiting in Taiwan: Physicians’ and nurses’ estimation vs. patients’ reported outcomes. Supportive Care in Cancer, 13(5), 277–286. https://doi.org/10.1007/s00520-004-0701-4
  23. Grunberg, S. M., Deuson, R. R., Mavros, P., Geling, O., Hansen, M., Cruciani, G., Daniele, B., De Pouvourville, G., Rubenstein, I. B., & Daugaard, G. (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 100(10), 2261–2268. https://doi.org/10.1002/cncr.20230
  24. Yeo, W., Lau, T. K., Kwok, C. C., Lee, K. H., Wong, K. H., Chan, M. Y., Kuan, F. C., Rizzi, G., Ruffo, P., & Chang, J. (2020). NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ Supportive & Palliative Care. Advance online publication. https://doi.org/10.1136/bmjspcare-2019-002037
  25. Bošnjak, S. M., Gralla, R. J., & Schwartzberg, L. (2017). Prevention of chemotherapy-induced nausea: The role of neurokinin-1 (NK1) receptor antagonists. Supportive Care in Cancer, 25(5), 1661–1671. https://doi.org/10.1007/s00520-017-3614-7
  26. Navari, R. M. (2010). Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncology, 6(7), 1073–1084. https://doi.org/10.2217/fon.10.74
  27. Schwartzberg, L. S., McLaughlin, T., Geller, B. R., Gabrail, N. Y., & Marks, S. M. (2018). Real-world efficacy: Intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. Journal of Comparative Effectiveness Research, 7(12), 1161–1170. https://doi.org/10.2217/cer-2018-0050
  28. Schilling, J., Hielscher, C., Hanusch, C., Kurbacher, C., Busch, S., & Karthaus, M. (2019). Abstract P1-11-10: Efficacy of NEPA as antiemetic prophylaxis in breast cancer patients receiving highly or moderately emetogenic chemotherapy – Interim results of a German prospective, non-interventional study. Cancer Research, 79(4_suppl), Article P1-11-10. https://doi.org/10.1158/1538-7445.SABCS18-P1-11-10
  29. Schwartzberg, L., Karthaus, M., Rossi, G., Borroni, B., Taylor, A., & Aapro, M. (2019). Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Cancer Medicine, 8(5), 2064–2073. https://doi.org/10.1002/cam4.1956
  30. Aapro, M., Ruffo, P., Panteri, R., Costa, S., & Piovesana, v. (2018). Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey. Cancer Reports, 1(3), Article e1127. https://doi.org/10.1002/cnr2.1127
  31. Ruddy, K., Mayer, E., & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59(1), 56–66. https://doi.org/10.3322/caac.20004
  32. Yeoh, Z. Y., Jaganathan, M., Rajaram, N., Sivanandan, K., Ho, G. F., Yip, C. H., Teo, S. H., & Schliemann, D. (2018). Feasibility of patient navigation to improve breast cancer care in Malaysia. Journal of Global Oncology, 4, 1–13. https://doi.org/10.1200/JGO.17.00125
  33. Ng, T. H., How, S. H., Kuan, Y. C., & Fauzi, A. R. (2012). Defaulters among lung cancer patients in a suburban district in a developing country. Annals of Thoracic Medicine, 7(1), 12–15. https://doi.org/10.4103/1817-1737.91555

引用

Md Yusof M, Abdullah MM, Yap BK, et al. Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Asia-Pac J Clin Oncol. 2022;18:419–427. https://doi.org/10.1111/ajco.13667

复制引用 已复制！
在此查看研究